Gastrointestinal Manifestations of Systemic Lupus Erythematosus

Chapter

Abstract

Gastrointestinal (GI) manifestations are common in patients with systemic lupus erythematosus (SLE). Sir William Osler was the first to emphasize the importance of GI manifestations in SLE and stressed that GI symptoms associated with SLE could mimic nearly any abdominal condition [1]. The GI tract is one of the most commonly affected systems in SLE. Incidence reports vary widely, but one autopsy study found that 60–70 % of SLE patients had evidence of previous peritonitis on post-mortem examination, even though only in 10 % of patients were the episodes clinically apparent while the patient was alive [2]. Other studies estimate the incidence of GI symptoms in SLE patients to be somewhere between 25 and 40 % [3–5]. Most GI manifestations are due to adverse reactions to potent medications and infection, while symptoms directly affecting the GI tract due to SLE are far less common than arthritis or nephritis in these patients [6].

Keywords

Lipase Diarrhea Cyclosporine Perforation Ibuprofen 

Sources

  1. 1.
    Osler W. On the visceral complications of erythema exudativum mulitforme. Am J Med Sci. 1895;110:629–46.CrossRefGoogle Scholar
  2. 2.
    Wallace DJ. Gastrointestinal manifestations and related liver and biliary disorders. In: Wallace DJ, Hahn BH, editors. Dubois’ lupus erythematosus. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 1993. p. 410–7.Google Scholar
  3. 3.
    Hoffman BI, Katz WA. The gastrointestinal manifestations of systemic lupus erythematosus: a review of the literature. Semin Arthritis Rheum. 1980;9:237.PubMedCrossRefGoogle Scholar
  4. 4.
    Jovaisas A, Kraag G. Acute gastrointestinal manifestations of systemic lupus erythematosus. Can J Surg. 1987;30:185.PubMedGoogle Scholar
  5. 5.
    Zizic TM, Classen JN, Stevens MB. Acute abdominal complications of systemic lupus erythematosus and polyarteritis nodosa. Am J Med. 1982;73:525.PubMedCrossRefGoogle Scholar
  6. 6.
    Tian XP, et al. Gastrointestinal involvement in systemic lupus erythematosus. World J Gastroenterol. 2010;16(24):2971–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Allison MC, Howatson AG, Torrance CJ, et al. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl J Med. 1992;327:749.PubMedCrossRefGoogle Scholar
  8. 8.
    Ginzler EM, Aranow C. Prevention and treatment of adverse effects of corticosteroids in systemic lupus erythematosus. Baillieres Clin Rheumatol. 1998;12:495.PubMedCrossRefGoogle Scholar
  9. 9.
    Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol. 1998;93:2037.PubMedCrossRefGoogle Scholar
  10. 10.
    Simon LS, Hatoum TH, Bittman RM, et al. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Fam Med. 1996;28:202.Google Scholar
  11. 11.
    Koch M, Dezi A, Ferrario F, Capurso I. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials. Arch Intern Med. 1996;156:2321.PubMedCrossRefGoogle Scholar
  12. 12.
    Lancaster-Smith MJ, Jaderberg ME, Jackson DA. Ranitidine in the treatment of non-steroidal anti-inflammatory drug associated gastric and duodenal ulcers. Gut. 1991;32:252.PubMedCrossRefGoogle Scholar
  13. 13.
    Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114(9):735–40.PubMedGoogle Scholar
  14. 14.
    Gabriel SE, Jaaklimainen L, Bombadier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med. 1991;115:787.PubMedGoogle Scholar
  15. 15.
    Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol. 2010;49(3):239–48.PubMedCrossRefGoogle Scholar
  16. 16.
    Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Saf. 2004;27(1):25–61.PubMedCrossRefGoogle Scholar
  17. 17.
    Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32:651.PubMedGoogle Scholar
  18. 18.
    Wong W, Hodge MG, Lewis A, et al. Resolution of cyclosporin-induced gingival hypertrophy with metronidazole. Lancet. 1994;343:986.PubMedCrossRefGoogle Scholar
  19. 19.
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661–2.PubMedCrossRefGoogle Scholar
  20. 20.
    Bazin E. Lecons theoriques et cliniques sur la scrofula. 2nd ed. Paris: A. Delahue; 1861.Google Scholar
  21. 21.
    Tan E, Cohen A, Fries J, Masi A, McShane D, Rothfield N, et al. Special article: the 1982 revised criteria for the classification of systemic lupus erthematosus. Arthritis Rheum. 1982;25:1271–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Sultan SM, Ioannou Y, Isenberg DA. A review of gastrointestinal manifestations of systemic lupus erythematosus. Rheumatology (Oxford) 1999;38:917.Google Scholar
  23. 23.
    Johnson A, Cavalcanti F, Gordon C, Nived O, Sturfelt G, Viner N, et al. Cross-sectional analysis of the differences between patients with systemic lupus erythematosus in England, Brazil and Sweden. Lupus. 1994;3:501–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Fries J, Holman HR. Systemic lupus erythematosus: a clinical analysis. Philadelphia: WB Saunders; 1975.Google Scholar
  25. 25.
    Vitali C, Doria A, Tincani A, Fabbri P, Balestrieri B, Galeazzi M, et al. International survey on the management of patients with SLE. I. General data on the participating centres and the results of questionnaire regarding mucocutaneous involvement. Clin Exp Rheumatol. 1996;14 Suppl 16:517–22.Google Scholar
  26. 26.
    Jakes J, Dubois E, Quismorio FJ. Antileprosy drugs and lupus erythematosus. Ann Intern Med. 1982;97:788.PubMedGoogle Scholar
  27. 27.
    Luce E, Presti C, Montemayor I, Crawford M. Detecting cardiac valvular pathology in patients with systemic lupus erythematosus. Spec Care Dentist. 1992;12:193–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Chua S, Dodd H, Saeed IT, Chakravarty K. Dysphagia in a patient with lupus and review of the literature. Lupus. 2002;11(5):322–4.PubMedCrossRefGoogle Scholar
  29. 29.
    Castrucci G, Alimandi L, Fichera A, Altomonte L, Zoli A. Changes in esophageal motility in patients with systemic lupus erythematosus: an esophago-manometric study. Minerva Dietol Gastroenterol. 1990;36:3–7.PubMedGoogle Scholar
  30. 30.
    Ramirez-Mata M, Reyes P, Alarcon-Segovia D, Garva R. Esophageal motility in systemic lupus erythematosus. Am J Dig Dis. 1974;19:132–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Lapadula G, Muolo P, Semeraro F, Covelli M, Brindicci D, Cuccorese G, et al. Esophageal motility disorders in the rheumatic diseases: a review of 150 patients. Clin Exp Rheumatol. 1994;12:512–21.Google Scholar
  32. 32.
    Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Associations Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135(4):1392–413. 1413.e1–e5.PubMedCrossRefGoogle Scholar
  33. 33.
    Gutierrez F, Valenzuela J, Ehresmann G, Quismorio F, Kitridou R. Esophageal dysfunction in patients with mixed connective tissue diseases and systemic lupus erythematosus. Dig Dis Sci. 1982;27:592–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Montecucco C, Caporali R, Cobianchi F, Negri C, Astaldi-Ricotti G. Antibodies to hn-RNP protein A1 in systemic lupus erythematosus: clinical association with Raynaud’s phenomenon and esophageal dysmotility. Clin Exp Rheumatol. 1992;10:223–7.PubMedGoogle Scholar
  35. 35.
    Saab S, Corr MP, Weisman MH. Corticosteroids and systemic lupus erythematosus. J Rheumatol. 1998;25:801.PubMedGoogle Scholar
  36. 36.
    Chey W, Wong B. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102:1808–25.PubMedCrossRefGoogle Scholar
  37. 37.
    Endo H, Kondo Y, Kawagoe K, Ohya TR, Yanagawa T, Asayama M, Hisatomi K, Teratani T, Yoneda M, Inamori M, Nakajima A, Matsuhashi N. Lupus enteritis detected by capsule endoscopy. Intern Med. 2007;46:1621–2.PubMedCrossRefGoogle Scholar
  38. 38.
    Buck AC, Serebro LH, Quinet RJ. Subacute abdominal pain requiring hospitalization in a systemic lupus erythematosus patient: a retrospective analysis and review of the literature. Lupus. 2001;10:491–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Kwok SK, Seo SH, Ju JH, Park KS, Yoon CH, Kim WU, Min JK, Park SH, Cho CS, Kim HY. Lupus enteritis: clinical characteristics, risk factor for relapse and association with anti-endothelial cell antibody. Lupus. 2007;16:803–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Del Papa N, Guidali L, Sala A, Buccellati C, Khamashta MA, Ichikawa K, Koike T, Balestrieri G, Tincani A, Hughes GR, Meroni PL. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum. 1997;40:551–61.PubMedCrossRefGoogle Scholar
  41. 41.
    Medina F, Ayala A, Jara LJ, Becerra M, Miranda JM, Fraga A. Acute abdomen in systemic lupus erythematosus: the importance of early laparotomy. Am J Med. 1997;103:100–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Kim YG, Ha HK, Nah SS, Lee CK, Moon HB, Yoo B. Acute abdominal pain in systemic lupus erythematosus: factors contributing to recurrence of lupus enteritis. Ann Rheum Dis. 2006;65:1537–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Medeiros DA, Isenberg DA. Systemic lupus erythematosus and ulcerative colitis. Lupus. 2009;18:762–3.PubMedCrossRefGoogle Scholar
  44. 44.
    Garcia-Porrua C, Gonzalez-Gay MA, Lancho A, Alvarez-Ferreira J. Systemic lupus erythematosus and ulcerative colitis: an uncommon association. Clin Exp Rheumatol. 1998;16:511.PubMedGoogle Scholar
  45. 45.
    Stevens HP, Ostlere LS, Rustin MH. Systemic lupus erythematosus in association with ulcerative colitis: related autoimmune diseases. Br J Dermatol. 1994;130:385–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Siurala M, Julkunen H, Tolvonen S, Pelkonen R, Saxen E, Pitkanen E. Digestive tract in collagen diseases. Acta Med Scand. 1965;178:13–25.PubMedCrossRefGoogle Scholar
  47. 47.
    Rustgi AK, Peppercorn MA. Gluten-sensitive enteropathy and systemic lupus erythematosus. Arch Intern Med. 1988;148:1583–4.PubMedCrossRefGoogle Scholar
  48. 48.
    Schuppan D. Current concepts in celiac disease pathogenesis. Gastroenterology. 2000;119(1):234–42.PubMedCrossRefGoogle Scholar
  49. 49.
    Zheng WJ, Tian XP, Li L, Jing HL, Li F, Zeng XF, Tang FL. Protein-losing enteropathy in systemic lupus erythematosus: analysis of the clinical features of fifteen patients. J Clin Rheumatol. 2007;13:313–6.PubMedCrossRefGoogle Scholar
  50. 50.
    Hung J, Wood CA, Woronik V, Vieira Jr JM, Barros RT. Protein-losing gastroenteropathy in a patient with systemic lupus erythematosus and antiphospholipid antibody syndrome simulating nephrotic syndrome. Nephrol Dial Transplant. 2006;21:2027–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Alexopoulou A, Andrianakos A, Dourakis SP. Intestinal pseudo-obstruction and ureterohydronephrosis as the presenting manifestations of relapse in a lupus patient. Lupus. 2004;13:954–6.PubMedCrossRefGoogle Scholar
  52. 52.
    Park FD, Lee JK, Madduri GD, Ghosh P. Generalized megaviscera of lupus: refractory intestinal pseudo-obstruction, ureterohydronephrosis and megacholedochus. World J Gastroenterol. 2009;15:3555–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Ceccato F, Salas A, Góngora V, Ruta S, Roverano S, Marcos JC, Garcìa M, Paira S. Chronic intestinal pseudo-obstruction in patients with systemic lupus erythematosus: report of four cases. Clin Rheumatol. 2008;27:399–402.PubMedCrossRefGoogle Scholar
  54. 54.
    Shahram F, Akbarian M, Davatchi F. Salmonella infection in systemic lupus erythematosus. Lupus. 1993;2:55–9.PubMedGoogle Scholar
  55. 55.
    Breuer GS, Baer A, Dahan D, Nesher G. Lupus-associated pancreatitis. Autoimmun Rev. 2006;5:314–8.PubMedCrossRefGoogle Scholar
  56. 56.
    van Hoek B. The spectrum of liver disease in systemic lupus erythematosus. Neth J Med. 1996;48:244–53.PubMedCrossRefGoogle Scholar
  57. 57.
    Miller MH, Urowitz MB, Gladman DD, Blendis LM. The liver in systemic lupus erythematosus. Q J Med. 1984;53:401–9.PubMedGoogle Scholar
  58. 58.
    Runyon BA, Larecque DR, Anuras S. The spectrum of liver disease in systemic lupus erythematosus. Report of 33 histologically proven cases and review of the literature. Am J Med. 1980;69:187.PubMedCrossRefGoogle Scholar
  59. 59.
    Mackay IR, Taft LI, Cowling DC. Lupoid hepatitis and the hepatic lesions of systemic lupus erythematosus. Lancet. 1959;7063:65–9.CrossRefGoogle Scholar
  60. 60.
    Irving KS, Sen D, Tahir H, Pilkington C, Isenberg DA. A comparison of autoimmune liver disease in juvenile and adult populations with systemic lupus erythematosus—a retrospective review of cases. Rheumatology (Oxford). 2007;46:1171–3.CrossRefGoogle Scholar
  61. 61.
    Arnett FC, Reichlin M. Lupus hepatitis: an under-recognized disease feature associated with autoantibodies to ribosomal P. Am J Med. 1995;99:465–72.PubMedCrossRefGoogle Scholar
  62. 62.
    Kaw R, Gota C, Bennett A, Barnes L, Calabrese L. Lupus-related hepatitis: complication of lupus or autoimmune association? Case report and review of the literature. Dig Dis Sci. 2006;51(4):813–8.PubMedCrossRefGoogle Scholar
  63. 63.
    Hallegua DS, Wallace DJ. Gastrointestinal manifestations of systemic lupus erythematosus. Curr Opin Rheumatol. 2000;12:379–85.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.Beth Israel Deaconess Medical CenterBostonUSA
  2. 2.Harvard Medical SchoolBostonUSA

Personalised recommendations